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Abstract: Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GD) are often found
to coexist but the sequential relationship of NAFLD and GD to each other remains controversial.
We prospectively evaluated the bidirectional relationship of NAFLD with GD. A cohort study
was performed on Korean adults who underwent a health checkup and were followed annually
or biennially for a mean of 6.0 years. Fatty liver and gallstones were diagnosed by ultrasound.
NAFLD was defined as hepatic steatosis on ultrasonography in the absence of excessive alcohol
use or other identifiable causes. The NAFLD severity was determined by non-invasive fibrosis
markers. Among 283,446 participants without either gallstones or cholecystectomy at baseline,
6440 participants developed gallstones. Among 219,641 participants without NAFLD at baseline,
49,301 participants developed NAFLD. The multivariable-adjusted hazard ratio (95% confidence
interval) for incident gallstone comparing the NAFLD group vs. the non-NAFLD group was 1.26
(1.17–1.35). Increased non-invasive fibrosis markers of NAFLD were positively associated with
an increased incidence of gallstones in a graded and dose-responsive manner (p-trend < 0.01).
The multivariable-adjusted hazard ratios (95% confidence intervals) for incident NAFLD comparing
gallstone and cholecystectomy to no GD were 1.14 (1.07–1.22) and 1.17 (1.03–1.33), respectively.
This large-scale cohort study of young and middle-aged individuals demonstrated a bidirectional
association between NAFLD and GD. NAFLD and its severity were independently associated with an
increased incidence of gallstones, while GD and cholecystectomy were also associated with incident
NAFLD. Our findings indicate that the conditions may affect each other, requiring further studies to
elucidate the potential mechanisms underlying this association.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is becoming one of the most common liver disorders in
parallel with the global increase in obesity and type 2 diabetes [1]. NAFLD encompasses a spectrum of
liver disorders ranging from simple steatosis to inflammatory steatohepatitis (NASH) with or without
fibrosis/cirrhosis and hepatocellular carcinoma [2,3]. In addition to its liver-related complications,
NAFLD is associated with significant non-liver morbidity, impaired health-related quality of life, and a
higher use of health care resources [4,5]. NAFLD has been traditionally considered a consequence
of metabolic syndrome (MetS), also known as insulin resistance syndrome, but the relationship of
NAFLD with MetS is complex, and a growing body of evidence suggests the NAFLD-MetS relationship
as being bidirectional in nature [6–11]. Gallstone disease (GD) is also a common condition whose
prevalence is increasing with the ongoing rise in obesity, and represents a major epidemiologic and
economic burden worldwide [12]. NAFLD and GD are commonly found to coexist [13–16] and have
similar associated risk factors, including insulin resistance, obesity, metabolic syndrome, and type 2
diabetes [12,17,18]. Insulin resistance is considered a pivotal feature of both NAFLD and cholesterol
gallstone [19,20]. Additionally, the severity of insulin resistance correlates with liver histology in
patients with NAFLD [17,21]. Until now, to our knowledge, only two longitudinal cohort studies
among Chinese and Taiwanese populations have examined the association between NAFLD and
GD, without consideration of hepatic fibrosis [22,23]. Furthermore, no longitudinal cohort study has
evaluated whether gallstones or cholecystectomy are associated with increased risk of developing
NAFLD. Recent reports suggest that the gallbladder and bile acids appear to play a role in systemic
metabolic regulation, and cholecystectomy itself may contribute to NAFLD development [18,24].
Currently, the sequential relationship of NAFLD and GD remains unclear, and, to the best of our
knowledge, no longitudinal cohort data on a bidirectional association between NAFLD and GD
are available.
We examined whether NAFLD and its severity, based on noninvasive fibrosis markers,
are associated with incident GD compared with no NAFLD, and sought determine whether gallstones
and cholecystectomy are associated with an increased risk of developing NAFLD in a large cohort of
Korean men and women who underwent a health screening program.
2. Methods
2.1. Study Population
The Kangbuk Samsung Health Study is a cohort study of South Korean adults who underwent a
comprehensive annual or biennial health examination at Kangbuk Samsung Hospital Total Healthcare
Center in Seoul and Suwon, South Korea [25,26]. More than 80% of the participants were employees
of various companies and local governmental organizations and their spouses. In South Korea,
the Industrial Safety and Health Law requires annual or biennial health screening exams for
all employees, offered free of charge. The remaining participants voluntarily registered for the
screening exams.
The present analysis included study participants who underwent the comprehensive health
examinations from January 1, 2002, to December 31, 2016, and who had at least one other screening
exam before December 31, 2017 (n = 353,637; Figure 1). We excluded 62,479 subjects who had any of
the following conditions at baseline: missing data for abdominal ultrasonography, body mass index
(BMI), or components of noninvasive fibrosis markers (n = 1092); history of malignancy (n = 4572);
known liver disease or current use of medications for liver disease (n = 17,757); a history of liver
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cirrhosis or findings of liver cirrhosis based on ultrasound (n = 96); alcohol intake of ≥30 g/day for
men or ≥20 g/day for women [1] (n = 37,768); positive serologic markers for hepatitis B or C virus
(n = 13,242); or use of medications associated with NAFLD within the past year such as valproate,
amiodarone, methotrexate, tamoxifen, or corticosteroids (n = 1101) [1]. Because some participants met
more than one exclusion criterion, a total of 291,158 participants were eligible for this study. For the
analysis of the impact of NAFLD on the development of gallstones, we excluded 7712 subjects with
either gallstones or cholecystectomy at baseline, leaving 283,446 to be included in the final analysis.
For the analysis of the impact of gallstones and cholecystectomy on incident NAFLD, 71,517 subjects
with NAFLD at baseline were excluded, leaving 219,641 to be included in the final analysis. This study
was approved by the Institutional Review Board of Kangbuk Samsung Hospital, which waived the
requirement for informed consent because we accessed only de-identified data routinely collected as
part of health screening examinations.
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Figure 1. Flow diagram for the selection of study subjects.
2.2. Measurements
Baseline and follow-up examinations were conducted at the Kangbuk Samsung Hospital Total
Healthcare Center [25]. Data on medical history, medication use, and health-related behaviors were
collected through a self-administered questionnaire, while the physical measurements, ultrasound,
and serum biochemical parameters were measured by trained staff during the health examinations.
All variables were assessed at each visit.
Blood pressure, height, weight and waist circumference were measured by trained nurses. Obesity
and abdominal obesity were defined as BMI ≥ 25 kg/m2 following Asian-specific criteria [27].
Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, a diastolic blood pressure
≥ 90 mmHg, a self-reported history of hypertension, or current use of anti-hypertensive medications.
Blood specimens were sampled from the antecubital vein after the individual had undergone
at least a 10-h fast. The fasting blood sample measurements included total cholesterol, low density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, alanine
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aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT),
glucose, uric acid, high sensitivity C-reactive protein (hsCRP), albumin, and platelet counts.
To assess the risk of severe NAFLD, three non-invasive indices of liver fibrosis were used: NAFLD
fibrosis score (NFS), fibrosis-4 (FIB-4), and aspartate transaminase to platelet ratio index (APRI).
NFS was calculated according to the following published formula: NFS = −1.675 + 0.037 × age
(years) + 0.094 × BMI (kg/m2) + 1.13 × impaired fasting glucose or diabetes (yes = 1, no = 0) +
0.99 × AST/ALT ratio − 0.013 × platelet (×109/L) − 0.66 × albumin (g/dL). Two cutoff points
were selected to categorize subjects with NAFLD into three groups according to their probability of
advanced fibrosis: high (NFS > 0.676), intermediate (NFS: 0.676 to−1.455), and low (NFS <−1.455) [28].
The FIB-4 index was calculated by the following formula: FIB-4 = (age (years) × AST (U/L))/(platelet
count (×109/L) × ALT (U/L)1/2). For histologically defined NASH with advanced fibrosis, the area
under the receiver-operating characteristic curve, sensitivity, and specificity of FIB-4 are 0.86 (95% CI,
0.78–0.94), 85%, and 65%, respectively [29]. Cut-off values from the curve were used to define low
(FIB-4 < 1.30), intermediate, and high (FIB-4 ≥ 2.67) probabilities of advanced fibrosis [30]. The APRI
was calculated by the following formula: APRI = 100 × (AST/upper limit of normal)/platelet count
(×109/L). Cut-offs for low and high probability of advanced fibrosis were 0.5 and 1.5, respectively [31].
Since a very small number of participants were identified as having NAFLD and high probability of
advanced fibrosis based on non-invasive fibrosis markers, we combined the intermediate and high
fibrosis score groups.
Abdominal ultrasound scans were performed by experienced radiologists, all unaware of the
study aims, using a 3.5 MHz probe. Images were captured in a standard fashion with the patient
in the supine position with the right arm raised above the head. The liver, gallbladder, pancreas,
kidneys and spleen were evaluated in a standard fashion at each visit. An ultrasonographic diagnosis
of fatty liver was determined based on known standard criteria, including a diffuse increase of fine
echoes in the liver parenchyma compared with kidney or spleen parenchyma, deep beam attenuation,
and bright vessel walls [32]. The inter-observer reliability and intra-observer reliability for fatty liver
diagnosis were substantial (kappa statistic of 0.74) and excellent (kappa statistic of 0.94), respectively.
NAFLD was defined as the presence of fatty liver in the absence of excessive alcohol use (a threshold
of < 20 g/day for women and < 30 g/day for men) or other identifiable cause, as described in the
exclusion criteria.
Gallstones were defined as ultrasound-documented gallstones by the presence of strong
intraluminal echoes that were gravity dependent or that attenuated ultrasound transmission (acoustic
shadowing) [33]. Cholecystectomy was defined as evidence of a cholecystectomy (a right upper
quadrant or epigastric scar and the absence of a gallbladder) [33]. The inter-observer reliability and
intra-observer reliability for gallstone diagnosis were excellent (kappa statistics of 0.90 and 0.96,
respectively).
2.3. Statistical Analyses
Student’s t-test for continuous variables with normal distribution, Kruskal-Wallis test for variables
with non-normal distribution, and a Chi-square test for categorical variables were used to compare the
characteristics of the study participants at baseline according to incident GD.
Incidence density was expressed as the number of cases divided by person-years. Follow-up for
each participant extended from the baseline exam until the development of the endpoint or the last
health exam. Since we knew that the endpoint had developed between two visits but did not know
the precise time, we used a parametric proportional hazard model to take into account this type of
interval censoring (stpm command in Stata) [34]. In these models, the baseline hazard function was
parameterized with restricted cubic splines in log time with four degrees of freedom. We estimated
the adjusted hazard ratios (aHR) with 95% confidence intervals (CI) for endpoints. We assessed the
proportional hazards assumption by examining graphs of estimated log(−log) survival; no violation
of the assumption was found.
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2.3.1. Baseline NAFLD and Incident GD
A cholecystectomy can be performed due to acalculous gallbladder diseases such as gallbladder
polyps, tumors, acalculous cholecystitis, and biliary dyskinesia, which collectively represent
between 5% and 30% of laparoscopic cholecystectomies [35,36]. Because the indications for the
cholecystectomies were not available, we used ultrasound-documented gallstones as the primary
endpoint. We estimated the adjusted hazard ratios (aHR) with 95% confidence intervals (CI) for
incidental gallstones by comparing NAFLD with a low fibrosis score and NAFLD with an intermediate
to high fibrosis score to the no-NAFLD group among subjects without gallstone disease at baseline.
The models were initially adjusted for age and sex and then further adjusted for BMI, study
center, year of examination, education level, smoking, alcohol intake, exercise, total calorie intake,
history of hypertension, history of diabetes, and medication for dyslipidemia. To assess whether
the relationship between NAFLD and incident GD was mediated by LDL-C, HDL-C, triglycerides,
HOMA-IR, or hsCRP, we included those variables in multivariable models. To determine the linear
trends of risk, the number of categories was used as a continuous variable and tested on each model.
We performed subgroup analysis according to the presence of obesity to evaluate the association
between NAFLD and gallstones in non-obese and obese individuals, since NAFLD is closely associated
with obesity, and adjustment for BMI may not be enough to control for the effects of obesity.
In sensitivity analyses, we analyzed the association between NAFLD and cholecystectomy as well.
We also performed a sensitivity analysis using fatty liver index as a surrogate marker of NAFLD
to examine an association between smoking and incident NAFLD. The fatty liver index (FLI) was
calculated according to the published formula [37]. The following cutoff values were used: FLI < 30
ruled out and FLI ≥ 60 meant fatty liver [37].
2.3.2. Baseline Gallstone, Cholecystectomy and Incident NAFLD.
The primary endpoint was incident NAFLD. Since studies have reported that cholecystectomy
itself was significantly associated with NAFLD, we estimated the aHR with 95% confidence intervals
(CI) for incidental NAFLD separately comparing gallstone and cholecystectomy to no GD among
subjects without NAFLD at baseline. The models were initially adjusted for age and sex and then
further adjusted for BMI, center, year of examination, education level, smoking, alcohol intake, exercise,
total calorie intake, history of hypertension, history of diabetes, and medication for dyslipidemia.
To assess whether the relationship between GD and incident NAFLD was mediated by LDL-C, HDL-C,
triglycerides, HOMA-IR, or hsCRP, we included those variables in the model.
Since the association between NAFLD and gallstones can differ by sex based on previous
study findings, we performed stratified analyses by sex (men vs. women). The interactions by
the subgroups were tested using likelihood ratio tests comparing models with versus without
multiplicative interaction terms.
Statistical analyses were performed using STATA version 15.0 (StataCorp LP, College Station,
Texas, TX, USA). All p values were 2-tailed, and statistical significance was set at p < 0.05.
3. Results
Baseline characteristics of 283,446 participants without GD at baseline are presented according
to the presence of incident GD (Table 1). At baseline, the mean (standard deviation) age and BMI of
the study subjects were 37.0 (8.0) years and 23.1 (3.2) kg/m2, respectively; 52.4% were male, and the
prevalence of NAFLD was 24.3%. NAFLD, obesity, diabetes mellitus, hypertension, BMI, glucose,
blood pressure (BP), total cholesterol, triglycerides, LDL-C, hepatic enzymes, hsCRP, and HOMA-IR
were positively associated with incident GD, and HDL-C and alcohol intake were negatively associated
with incident GD.
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Table 1. Baseline characteristics of study participants according to incident gallstones by sex (n = 283,446).
Characteristic
Men (n = 148,593)
p Value
Women (n = 134,853)
p Value
No Incident Gallstones Incident Gallstones No Incident Gallstones Incident Gallstones
Number 144,948 3645 132,058 2795
Age (years) a 37.0 (7.8) 37.9 (8.3) <0.001 36.9 (8.3) 36.8 (7.7) 0.260
Current smoker (%) 38.0 40.4 0.004 2.2 2.5 0.303
Alcohol intake (%) b 45.1 40.5 <0.001 7.4 6.0 0.007
Vigorous exercise (%) c 15.0 12.8 <0.001 12.7 11.8 0.141
Higher education (%) d 86.8 85.9 0.210 72.5 71.1 0.141
Fatty liver (%) 37.2 48.6 <0.001 9.7 17.5 <0.001
Diabetes mellitus (%) 3.0 4.0 <0.001 1.4 2.0 0.008
Hypertension (%) 15.2 19.0 <0.001 5.6 7.5 <0.001
Medication for dyslipidemia (%) 1.2 1.3 0.490 0.9 0.7 0.303
Obesity (%) 37.4 48.1 <0.001 12.1 23.5 <0.001
BMI (kg/m2) 24.3 (2.9) 25.1 (3.0) <0.001 21.7 (2.9) 22.8 (3.6) <0.001
Systolic BP (mmHg) a 115.9 (12.2) 117.3 (12.4) <0.001 105.3 (12.8) 107.8 (14.0) <0.001
Diastolic BP (mmHg) a 74.9 (9.3) 76.4 (9.4) <0.001 67.1 (9.0) 68.7 (9.7) <0.001
Glucose (mg/dL) a 95.2 (14.7) 96.4 (16.9) <0.001 90.9 (11.5) 92.4 (13.7) <0.001
Total cholesterol (mg/ dL) a 197.8 (34.2) 201.7 (36.0) <0.001 185.8 (32.8) 187.3 (34.2) 0.022
LDL-C (mg/ dL) a 121.5 (30.2) 123.0 (30.8) 0.002 106.1 (28.5) 108.0 (29.5) <0.001
HDL-C (mg/ dL) a 52.2 (11.5) 49.9 (10.7) <0.001 63.0 (14.1) 59.4 (13.4) <0.001
Triglycerides (mg/ dL) e 116 (82–166) 129 (93–186) <0.001 73 (56–100) 82 (60–116) <0.001
Albumin (g/dL) a 4.7 (0.2) 4.6 (0.2) <0.001 4.5 (0.2) 4.5 (0.2) 0.342
AST (U/L) e 23 (19–28) 24 (20–29) <0.001 18 (16–22) 19 (16–22) <0.001
ALT (U/L) e 24 (18–35) 28 (20–41) <0.001 14 (11–18) 15 (12–20) <0.001
GGT (U/L) e 26 (18–41) 31 (20–48) <0.001 12 (9–16) 13 (10–19) <0.001
hsCRP (mg/L) e 0.5 (0.3–1.0) 0.7 (0.4–1.3) <0.001 0.3 (0.1–0.7) 0.4 (0.2–1.0) <0.001
HOMA-IR e 1.6 (1.1–2.2) 1.9 (1.3–2.5) <0.001 1.4 (0.9–2.0) 1.7 (1.2–2.3) <0.001
Data are a mean (standard deviation); e median (interquartile range), or percentage; b ≥ 10 g of ethanol per day; c ≥ 3 times per week; d ≥ college graduate; Abbreviations: ALT, alanine
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; GGT, gamma-glutamyltransferase; HDL-C, high-density lipoprotein-cholesterol; hsCRP,
high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol.
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3.1. Baseline NAFLD and Incident GD
During 1,703,427.0 person-years of follow-up, 6640 participants developed gallstones (overall
incidence rate 3.8 per 1000 person-years; 3.9 per 1000 person-years in men and 3.7 per 1000 person-years
in women) (Table 2). The median follow-up period for participants was 5.0 years (interquartile range
2.4–8.9, up to 15.8 years). After adjusting for age, sex, BMI, center, year of examination, education
level, smoking, alcohol intake, exercise, history of hypertension, history of diabetes, and medication
for dyslipidemia, the aHR (95% CI) for incident gallstone comparing the NAFLD group vs. the no
NAFLD group was 1.32 (1.22–1.43) in men and 1.35 (1.18–1.53) in women. The association persisted
after adjusting for metabolic parameters including LDL-C, HDL-C, triglycerides, HOMA-IR, or hsCRP.
The risk for incidental gallstone did not vary significantly by gender (p for interaction = 0.745).
In subgroup analysis stratified by the presence of obesity, defined as BMI ≥ 25 kg/m2, NAFLD
was significantly associated with increased risk of incident gallstone in both non-obese and obese
individuals (Appendix A).
Table 3 shows the association between NAFLD and its severity based on non-invasive fibrosis
markers and the development of gallstones. In multivariate-adjusted models, an increase across
baseline NAFLD categories based on NFS predicted an increase in the incidence of gallstones in a
graded and dose-responsive manner (p-rend < 0.01). The aHRs (95% CI) for gallstones comparing
NAFLD with low NFS and NAFLD with intermediate or high NFS vs. no NAFLD were 1.30 (1.21–1.39)
and 1.54 (1.30–1.82), respectively (Table 3 and model 1). Using other fibrosis markers based on
FIB-4 and APRI, the results were similar for NAFLD with a low fibrosis score and NAFLD with an
intermediate or high score. In the sensitivity analysis (Appendix B), the association of NAFLD based
on fatty liver index with incident gallstone was similarly observed.
We also examined the association of NAFLD with the risk for incidental cholecystectomy or
a combined endpoint including either gallstone or cholecystectomy (Appendix C). The association
between NAFLD and the development of either gallstone or cholecystectomy was observed in both
men and women. However, the association between NAFLD and incident cholecystectomy tended to
be stronger in women than in men (p for interaction = 0.033).
3.2. Baseline Gallstone, Cholecystectomy and Incident NAFLD
During 1,165,454.7 person-years of follow-up, 49,301 participants developed NAFLD (overall
incidence rate 42.3 per 1000 person-years; 68.0 per 1000 person-years in men and 23.5 per 1000
person-years in women) (Table 4). For men, multivariable-adjusted HR (95% CI) for incident NAFLD
comparing GD and cholecystectomy to no GD were 1.12 (1.03–1.22) and 1.21 (1.04–1.42), respectively,
while for women. the corresponding HR (95% CI) were 1.23 (1.13–1.35) and 0.98 (0.80–1.19), respectively.
The increased risk for incidental NAFLD with cholecystectomy was evident in men but not in women
(p for interaction = 0.002).
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Table 2. The associations between nonalcoholic fatty liver disease (NAFLD) and the development of gallstones.




HR a (95% CI)
Multivariate HR a (95% CI)
Model 1 Model 2
Total (n = 283,446)
No NAFLD 214,446 1,295,745.6 4180 3.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 69,000 407,681.4 2260 5.5 1.77 (1.68–1.87) 1.31 (1.22–1.40) 1.26 (1.17–1.35)
Men (n = 148,593)
No NAFLD 121,518 605,332.7 2307 3.1 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 13,335 339,409.0 488 5.2 1.67 (1.57–1.79) 1.32 (1.22–1.43) 1.26 (1.15–1.37)
Women (n = 134,853)
No. NAFLD 92,928 690,412.9 1873 3.3 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 55,665 68,272.5 1772 7.1 2.17 (1.96–2.41) 1.35 (1.18–1.53) 1.28 (1.11–1.46)
a Estimated from parametric proportional hazard models. The p value for the interaction of sex and NAFLD on the risk of incident gallstones was 0.740. Multivariable adjusted model
1 was adjusted for age, sex, BMI, center, year of examination, education level, smoking, alcohol intake, exercise, total calorie intake, history of hypertension, history of diabetes and
medication for dyslipidemia, except sex in the stratified analysis by sex; model 2: model 1 plus adjusted for LDL-C, HDL-C, triglycerides, HOMA-IR, or hsCRP. Abbreviations: BMI, body
mass index; CI, confidence intervals; HDL-C, high-density lipoprotein-cholesterol; HR, hazard ratios; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment
of insulin resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
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Table 3. The associations between nonalcoholic fatty liver disease (NAFLD) and its severity based on non-invasive fibrosis markers and the development of gallstones.




HR a (95% CI)
Multivariate HR a (95% CI)
Model 1 Model 2
Based on NFS
No NAFLD 214,446 1,295,745.6 4180 3.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD, Low NFS 63,985 384,074.4 2056 5.4 1.73 (1.64–1.83) 1.30 (1.21–1.39) 1.25 (1.16–1.34)
NAFLD, Intermediate or 5015 23,607.0 204 8.6 2.40 (2.07–2.78) 1.54 (1.30–1.82) 1.50 (1.26–1.78)
high NFS
p for trend <0.001 <0.001 <0.001
Based on FIB 4
No NAFLD 214,446 1,295,745.6 4180 3.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD, Low FIB 4 65,526 392,234.6 2157 5.5 1.77 (1.68–1.88) 1.31 (1.23–1.41) 1.26 (1.17–1.36)
NAFLD, Intermediate or 3474 15,446.8 103 6.7 1.68 (1.37–2.06) 1.20 (0.95–1.51) 1.21 (0.96–1.53)
high FIB 4
p for trend <0.001 <0.001 <0.001
Based on APRI
No NAFLD 214,446 1,295,745.6 4180 3.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD, Low APRI 64,537 381,044.8 2101 5.5 1.76 (1.67–1.86) 1.31 (1.22–1.40) 1.26 (1.17–1.36)
NAFLD, Intermediate or 4463 26,636.6 159 6.0 1.89 (1.61–2.22) 1.31 (1.10–1.57) 1.26 (1.05–1.50)
high APRI
p for trend <0.001 <0.001 <0.001
a Estimated from parametric proportional hazard models. Multivariable adjusted model 1 was adjusted for age, sex, BMI, center, year of examination, education level, smoking, alcohol
intake, exercise, total calorie intake, history of hypertension, history of diabetes and medication for dyslipidemia; model 2: model 1 plus adjusted for LDL-C, HDL-C, triglycerides,
HOMA-IR, or hsCRP. Abbreviations: APRI, aspartate transaminase to platelet ratio index; CI, confidence intervals; FIB-4, fibrosis 4; HDL-C, high-density lipoprotein-cholesterol; HR,
hazard ratios; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic
fatty liver disease; NFS, NAFLD fibrosis score.
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Table 4. The associations between gallstone, cholecystectomy and the development of nonalcoholic fatty liver disease (NAFLD) (n = 219,641).




HR a (95% CI)
Multivariate HR a (95% CI)
Model 1 Model 2
Total (n = 219,641)
No gallstone disease 214,446 1,141,715.8 47,992 42.0 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gallstone 4073 19,015.1 1051 55.3 1.36 (1.28–1.44) 1.16 (1.09–1.24) 1.14 (1.07–1.22)
Cholecystectomy 1122 4723.8 258 54.6 1.23 (1.09–1.39) 1.10 (0.97–1.25) 1.17 (1.03–1.33)
Men (n = 94,865)
No gallstone disease 92,928 484,621.6 32,782 67.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gallstone 1494 6653.3 570 85.7 1.26 (1.16–1.37) 1.12 (1.03–1.22) 1.10 (1.01–1.20)
Cholecystectomy 443 1763.4 154 87.3 1.29 (1.10–1.51) 1.21 (1.04–1.42) 1.29 (1.10–1.52)
Women (n = 124,776)
No gallstone disease 121,518 657,094.2 15,210 23.1 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gallstone 2579 12,361.8 481 38.9 1.53 (1.40–1.68) 1.23 (1.13–1.35) 1.15 (1.05–1.27)
Cholecystectomy 679 2960.5 104 35.1 1.17 (0.96–1.42) 0.98 (0.80–1.19) 1.05 (0.86–1.28)
a Estimated from parametric proportional hazard models. The p-value for the interaction of sex and gallstone disease on the risk of incident NAFLD was 0.002. Multivariable adjusted
model 1 was adjusted for age, sex, BMI, center, year of examination, education level, smoking, alcohol intake, exercise, total calorie intake, history of hypertension, history of diabetes, and
medication for dyslipidemia, except sex in the stratified analysis by sex; model 2: model 1 plus adjustment for LDL-C, HDL-C, triglycerides, HOMA-IR, or hsCRP. Abbreviations: CI,
confidence intervals; HDL-C, high-density lipoprotein-cholesterol; HR, hazard ratios; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin
resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
J. Clin. Med. 2018, 7, 458 11 of 21
4. Discussion
In this large-scale cohort study of young and middle-ged individuals, we examined the
bidirectional relationship between NAFLD and GD during a median of 5 years of follow-up.
We found that in one direction, NAFLD was associated with an increased risk of developing GD,
and in the other direction, gallstone and cholecystectomy were associated with an increased risk of
incident NAFLD. Using the non-invasive fibrosis markers, subjects with NAFLD and intermediate
or high NFS had the highest incidence of gallstones, but even with a low probability of hepatic
fibrosis based on fibrosis markers, NAFLD was significantly associated with the development of
gallstones. These associations persisted even after adjusting for possible confounders, lipid profiles,
HOMA-IR, and hsCRP, suggesting bidirectional and independent relationships exist between NAFLD
and gallstones.
Previous studies, which have included mostly cross-sectional studies and only a few cohort
studies, have evaluated the association between NAFLD and GD, but their relationship remains
controversial [38–40]. While some of these cross-sectional studies showed an increased prevalence of
GD in patients with NAFLD, others reported a relationship in the other direction, showing an increased
prevalence of NAFLD in patients with GD or cholecystectomy [13–16,38,41,42]. Until now, only two
cohort studies on the association between NAFLD and GD were available [22,23]. A cohort study
of 11,200 Chinese health checkup examinees over 6 years demonstrated that NAFLD was associated
with an increased incidence of gallstones, with a stronger association in female participants [23].
The other cohort study, of 1296 Chinese adults with a mean follow-up of 3.51 years, also reported a
positive association of NAFLD with GD (22). Likewise, both studies reported that NAFLD predicts the
development of GD. However, in a recent pilot study of non-obese, middle-aged patients, liver fat as
shown by abdominal magnetic resonance imaging was significantly increased in patients who had
undergone cholecystectomy 2 years ago (n = 26) compared to normal patients (n = 16) [43]. Although
the association between NAFLD and GD has been hypothesized to be bidirectional, no cohort studies
have examined this hypothesis before our study. To the best of our knowledge, this is by far the
largest longitudinal cohort study demonstrating a prospective bidirectional relationship between
NAFLD and GD, while accounting for a considerable number of possible confounders. NAFLD was
independently associated with an increased risk for developing gallstones in both men and women.
Even in nonobese men and women, positive association between NAFLD and incident gallstones
was observed; thus, the presence of obesity and other metabolic factors could not fully explain these
associations. Indeed, NAFLD, even in nonobese individuals, is associated with insulin resistance,
impaired glucose tolerance, and metabolic syndrome, all of which are risk factors for GD [11,44–46].
Additionally, NAFLD overproduces cholesterol and alters cholesterol metabolism independent of
obesity, which might contribute to the formation of cholesterol gallstones [11,47,48].
With regard to NAFLD severity, a recent cross-sectional study in patients with biopsy-proven
NAFLD reported that the prevalence of GD increased with advancing fibrosis [41]. In our study,
increasing severity of NAFLD from low to intermediate or high NFS at baseline was associated with
higher incidence of gallstones in a dose-responsive manner, but even NAFLD with low NFS was also
associated with a higher incidence of gallstones when compared with no NAFLD. However, the small
number of patients with a high probability of fibrosis in the study did not allow a separate category
for a more severe form of NAFLD.
In the other direction, we also demonstrated that both GD and cholecystectomy were associated
with an increased risk of developing NAFLD. A significantly increased risk of incident NAFLD was
observed in both men and women with gallstones but only in men with cholecystectomy. Even though
the number of female participants was large, the incidence of NAFLD was much lower in women than
in men (23.5 per 1000 person-years in women and 68.0 per 1000 person-years in men), resulting in a
lack of power to detect an association between cholecystectomy and incident NAFLD in the relatively
lean and young female participants.
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Though there have been only limited data on the incidence rate of GD among the general
population, the incidence of gallstones was lower in our study (3.9 per 1000 person-years in men and 3.7
per 1000 person-years in women) than in other populations [49,50]. This difference could be explained
by age and ethnic differences. The frequency of gallstones increases with age, escalating markedly after
40 years of age by 4–10-fold [50], and in our study, 72.9% of the subjects were younger than 40 years.
Ethnically, a lower prevalence of GD has been reported for Asian populations compared to Western
populations [51]. Regarding gallstone composition, pigment stones still comprise a relatively higher
proportion of gallstones in East Asians; however, the epidemiological and composition characteristics
of GD have become similar to those seen in Western countries [52]. If pigment stones are included in
this study, the resultant association between NAFLD and gallstones may be diluted due to the different
pathogenesis of gallstone types.
The mechanisms underlying the bidirectional association between NAFLD and gallstones
are incompletely understood. Insulin resistance, a key feature of NAFLD development and
progression, could play a major role in the pathogenesis of gallstones by favoring the production of
cholesterol-supersaturated bile, inducing a lithogenic bile salt profile and altering gallbladder function,
all of which are key features in the pathogenesis of cholesterol gallstones [19,38]. Indeed, the production
of bile supersaturated with cholesterol from the liver is a key early metabolic event underlying
cholesterol lithogenesis [53]. NAFLD is characterized by disordered lipid metabolism, inhibition of
fatty acid oxidation, and enhanced lipogenesis [53]. Therefore, these metabolic milieus in NAFLD may
trigger pathophysiologic processes associated with gallstone formation. However, the relationship
between insulin resistance and GD may not be unilateral, since gallbladder dysfunction has been
associated with NAFLD and other insulin resistance-associated conditions [38,43]. In our study,
even after adjustment for HOMA-IR, the bidirectional association between NAFLD and gallstones
persisted. Several systemic metabolic changes following cholecystectomy have been linked to the
pathophysiology of NAFLD in previous studies [38]. Glucose and lipid metabolism may be affected
by alterations in bile acid metabolism in the absence of gall bladder, contributing to development of
NAFLD [54]. The altered circulation of bile acids exerts effects on hepatic lipid and glucose metabolism
modulated via activity of bile acid receptors such as the farnesoid X receptor and TGR5, leading to
gene expression changes in the liver that may lead to development of NAFLD [55,56]. Another possible
mechanism is the decreased level of fibrosis growth factor 19 (FGF19), which is mainly secreted by
gall bladder mucosa, after cholecystectomy [57]. FGF19 regulates the de novo synthesis of bile salts,
lipogenesis, and energy homeostasis [58,59] and has been shown to have inhibitory effects on hepatic
fatty acid synthesis [60,61]. Therefore, decreased FGF19 level following cholecystectomy may alter
metabolic regulation, favoring triglyceride accumulation in the liver [58,62]. In fact, lower serum level
of FGF19 was found to be associated with increased risk of NAFLD [63]. Further prospective studies
are warranted to elucidate the mechanisms for an increased risk of NAFLD after cholecystectomy.
In our study, the association between NAFLD and development of gallstone was similarly
observed in both men and women, whereas the association between NAFLD and incident
cholecystectomy tended to be stronger in women than in men (p for interaction = 0.033). NAFLD,
a sexually dimorphic disease, more often affects men, but gallstones are more common in
women [64,65]. Similarly, in our study, men were found to be more likely to have NAFLD, while women
were more likely to develop gallstones. Previous studies showed that the prevalence of cholecystectomy
was generally higher in women, which was also consistent across different ethnic groups [33,66].
The pronounced risk of incident cholecystectomy in women with NAFLD seen in our study might
be correlated to a higher likelihood of having symptomatic GD in women, but its mechanism is not
clearly understood. Previous studies have reported the stronger association of obesity with the risk
of symptomatic GD in women than in men, possibly due to the role of estrogen secreted by adipose
tissue [67,68]; estrogen has also been linked to the increased risk of gallstones and cholecystectomy
in women [69,70]. Similarly, NAFLD and the effect of estrogen in women might act additively or
synergistically in contributing to the development of symptomatic gallstones. However, further studies
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are needed to fully explain the role of NAFLD in the development of gallstones as well as the role
of gallstones or cholecystectomy in the development of NAFLD while considering the existence of
different effects by sex.
The study had several limitations. First, NAFLD was diagnosed based on ultrasound results,
while liver biopsy is regarded as the gold standard. However, ultrasound is highly accurate for
steatosis and is widely used clinically and in population-based studies [71]. Second, the information on
the indications for cholecystectomy was not available; thus, we could not differentiate cholecystectomy
unrelated to gallstones [35,36]. However, the majority of gallstones are not associated with
symptoms [72]; thus, incidental asymptomatic gallstones as a separate outcome in our study could lead
to a better understanding of the development of gallstones. Finally, our findings from relatively healthy
young and middle-aged Korean men and women may not be generalizable to other populations with
different ages or race/ethnicity, or in different settings.
The major strength of our study was that NAFLD and gallstones diagnosed with ultrasound
were assessed repeatedly over time along with other confounders, which allowed us to evaluate the
temporal association between NAFLD and the development of asymptomatic gallstones. In addition
to the large sample size, our study population was relatively young and healthy, and thus our findings
may be less likely to be affected by confounding or selection biases due to comorbidities.
5. Conclusions
In conclusion, this cohort study demonstrated a bidirectional and longitudinal relationship
between NAFLD and GD. NAFLD and non-invasive fibrosis markers were independently associated
with an increased incidence of gallstones, while gallstones and cholecystectomy were also associated
with incident NAFLD. Our findings indicate that the conditions may affect each other, requiring further
studies to elucidate the potential mechanisms underlying this association.
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Appendix A
Table A1. The associations between nonalcoholic fatty liver disease (NAFLD) and development of gallstones by the presence of obesity, defined as BMI ≥ 25 kg/m2.




HR a (95% CI)
Multivariate HR a (95% CI)
Model 1 Model 2
Men
BMI < 25 kg/m2
No NAFLD 72,546 473,899.9 1333 2.8 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 20,146 122,294.6 560 4.6 1.59 (1.44–1.75) 1.53 (1.37–1.71) 1.38 (1.22–1.56)
BMI ≥ 25 kg/m2
No NAFLD 20,382 131,432.8 540 4.1 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 35,519 217,114.3 1212 5.6 1.37 (1.24–1.52) 1.37 (1.22–1.53) 1.24 (1.10–1.40)
Women
BMI < 25 kg/m2
No NAFLD 112,024 635,857.6 1969 3.1 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 6230 32,165.6 168 5.2 1.70 (1.45–1.99) 1.64 (1.37–1.97) 1.36 (1.12–1.65)
BMI ≥ 25 kg/m2
No NAFLD 9494 54,555.3 338 6.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 7105 36,106.9 320 8.9 1.51 (1.30–1.76) 1.42 (1.19–1.69) 1.38 (1.14–1.66)
a Estimated from parametric proportional hazard models. The p value for the interaction of obesity and NAFLD for the risk of incident gallstones was 0.300 in women, and 0.170 in men.
Multivariable adjusted model 1 was adjusted for age, sex, center, year of examination, education level, smoking, alcohol intake, exercise, total calorie intake, history of hypertension,
history of diabetes, and medication for dyslipidemia; model 2 included model 1 plus adjustments for LDL-C, HDL-C, triglycerides, HOMA-IR, and hsCRP. Abbreviations: BMI, body mass
index; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; HOMA-IR, Homeostasis Model Assessment of
Insulin Resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
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Appendix B
Table A2. The associations between fatty liver index (FLI) and the development of gallstones (n = 194,666).




HR a (95% CI)
Multivariate HR a (95% CI)
Model 1 Model 2
Total
FLI <30 142,201 686,999.9 2197 3.2 1.00 (reference) 1.00 (reference) 1.00 (reference)
FLI 30–<60 34,267 173,595.0 876 5.0 1.70 (1.55–1.85) 1.31 (1.17–1.46) 1.22 (1.08–1.38)
FLI ≥60 18,198 89,353.3 572 6.4 2.25 (2.03–2.49) 1.47 (1.27–1.71) 1.29 (1.08–1.54)
p for trend <0.001 <0.001 0.002
Men
FLI <30 52,982 272,555.5 795 2.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
FLI 30–<60 29,360 152,751.1 712 4.7 1.51 (1.36–1.67) 1.29 (1.13–1.48) 1.21 (1.05–1.41)
FLI ≥60 16,556 82,794.1 491 5.9 1.98 (1.77–2.21) 1.52 (1.27–1.82) 1.30 (1.04–1.63)
p for trend <0.001 <0.001 0.013
Women
FLI <30 89,219 414,444.4 1402 3.3 1.00 (reference) 1.00 (reference) 1.00 (reference)
FLI 30–<60 4907 20,843.9 164 7.8 2.36 (2.00–2.79) 1.38 (1.11–1.71) 1.24 (0.98–1.56)
FLI ≥60 1642 6559.2 81 12.3 3.83 (3.05–4.81) 1.46 (1.05–2.04) 1.31 (0.91–1.89)
p for trend <0.001 0.004 0.074
a estimated from parametric proportional hazard model. The p-value for the interaction of sex and FLI on the risk of incident gallstone was 0.503. Multivariable adjusted model 1 was
adjusted for age, sex, BMI, center, year of examination, education level, smoking, alcohol intake, exercise, total calorie intake, history of hypertension, history of diabetes and medication
for dyslipidemia, except sex in the stratified analysis by sex; model 2: model 1 plus adjusted for LDL-C, HDL-C, triglycerides, HOMA-IR, or hsCRP. Abbreviations: CI, confidence intervals;
FLI, fatty liver index; HDL-C, high-density lipoprotein-cholesterol; HR, hazard ratios; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin
resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
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Appendix C
Table A3. The associations between nonalcoholic fatty liver disease (NAFLD) and the development of gallstones or cholecystectomy (n = 283,446).




HR a (95% CI)
Multivariate HR a (95% CI)
Model 1 Model 2
Gallstone or cholecystecomty
Total
No NAFLD 214,446 1,299,654.6 4927 3.8 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 69,000 409,552.0 2612 6.4 1.73 (1.64–1.82) 1.28 (1.20–1.37) 1.24 (1.16–1.33)
Men
No NAFLD 92,928 607,142.6 2207 3.6 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 55,665 340,888.9 2036 6.0 1.63 (1.53–1.73) 1.29 (1.20–1.39) 1.23 (1.14–1.34)
Women
No NAFLD 121,518 692,512.0 2720 3.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 13,335 68,663.1 576 8.4 2.11 (1.93–2.32) 1.33 (1.18–1.50) 1.28 (1.13–1.45)
Cholecystectomy
Total
No NAFLD 214,446 1,311,709.6 1150 0.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 69,000 415,994.8 556 1.3 1.56 (1.40–1.74) 1.10 (0.96–1.26) 1.10 (0.95–1.27)
Men
No NAFLD 92,928 613,204.5 543 0.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 55,665 346,147.1 424 1.2 1.40 (1.24–1.59) 1.06 (0.90–1.25) 1.04 (0.88–1.24)
Women
No NAFLD 121,518 698,505.0 607 0.9 1.00 (reference) 1.00 (reference) 1.00 (reference)
NAFLD 13,335 69,847.7 132 1.9 2.03 (1.67–2.47) 1.30 (1.01–1.68) 1.26 (0.96–1.64)
a Estimated from parametric proportional hazard model. Multivariable adjusted model 1 was adjusted for age, sex, BMI, center, year of examination, education level, smoking, alcohol
intake, exercise, total calorie intake, history of hypertension, history of diabetes, and medication for dyslipidemia, except sex in the stratified analysis by sex; model 2: model 1 plus
adjusted for LDL-C, HDL-C, triglycerides, HOMA-IR, or hsCRP. Abbreviations: CI, confidence intervals; HDL-C, high-density lipoprotein-cholesterol; HR, hazard ratios; hsCRP, high
sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease. The
p-value for the interaction of sex and NAFLD on the risk of incident gallstone disease (gallstone or cholecystectomy) was 0.511. The p-value for the interaction of sex and NAFLD on the
risk of incident cholecystectomy was 0.033.
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Appendix D
Table A4. The factors associated with NAFLD and GD at baseline before prospective longitudinal
analysis from which persons with NAFLD or GD at baseline were excluded.
Multivariable-Adjusted Odds
Ratios (95% CI) for NAFLD
Multivariable-Adjusted Odds
Ratios (95% CI) for GD
Age per 10-year increment 1.16 (1.14–1.19) 1.71 (1.65–1.76)
Male 2.49 (2.40–2.59) 0.61 (0.56–0.66)
Suwon center 1.38 (1.34–1.41) 1.04 (0.98–1.11)
year of screening exam per 1-year 1.06 (1.05–1.06) 1.04 (1.03–1.05)
Education level ≥ college
graduate 1.15 (1.11–1.19) 1.31 (1.22–1.42)
Alcohol intake
<10 g of ethanol per day 0.88 (0.85–0.91) 0.95 (0.89–1.02)
≥10 g of ethanol per day 0.72 (0.69–0.75) 0.86 (0.79–0.94)
Smoking
Ever smoker 1.01 (0.97–1.05) 1.08 (0.99–1.19)
Never smoker 0.93 (0.89–0.96) 1.13 (1.04–1.24)
Vigorous exercise ≥ 3 times per
week 0.82 (0.79–0.85) 0.99 (0.91–1.07)
History of hypertension 1.10 (1.05–1.16) 0.96 (0.86–1.06)
History of diabetes 1.82 (1.65–2.02) 1.01 (0.85–1.20)
Medication for dyslipidemia 1.62 (1.44–1.83) 0.89 (0.72–1.10)
BMI per 1 SD increment 2.74 (2.69–2.79) 1.23 (1.19–1.27)
LDL-C per 1 SD increment 1.33 (1.32–1.35) 0.96 (0.93–0.99)
HDL-C per 1 SD increment 0.73 (0.72–0.74) 0.93 (0.90–0.96)
TC per 1 SD increment 1.59 (1.57–1.62) 0.93 (0.89–0.96)
HOMA-IR per 1 SD increment 1.71 (1.68–1.74) 1.15 (1.11–1.18)
hsCRP per 1 SD increment 1.30 (1.28–1.31) 1.14 (1.11–1.18)
Estimated from logistic regression models. Multivariate models are adjusted for all other variables listed for
the model.
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